Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2016 by National Cancer Institute (NCI)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01303341
First received: February 22, 2011
Last updated: December 6, 2016
Last verified: December 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)